J Immunother Cancer
antineoplastic protocols; chimeric antigen; guidelines as topic; hematological neoplasms; immunotherapy; receptors
Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.
Boyiadzis, Michael M; Aksentijevich, Ivan; Arber, Daniel A; Barrett, John; Brentjens, Renier J; Brufsky, Jill; Cortes, Jorge; De Lima, Marcos; Forman, Stephen J; Fuchs, Ephraim J; Fukas, Linda J; Gore, Steven D; Litzow, Mark R; Miller, Jeffrey S; Pagel, John M; Waller, Edmund K; and Tallman, Martin S, "The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia." (2020). Articles, Abstracts, and Reports. 3899.